A phase 3 randomized, open-label study of pasritamig (JNJ-78278343), a T-cell engager targeting human kallikrein-2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rana R. McKay, Kai-Jie Yu, Teresa Alonso Gordoa, Johann S. De Bono, Daniel J. George, Boris A. Hadaschik, Aaron Richard Hansen, Manish R. Patel, Fred Saad, Armelle Vinceneux, Qiang Wei, Daphne Y. C. Wu, Mykhailo Tatarenko, Nicky Pieters, Shiva Dibaj, Sherry Chia-E Wang, Dorie Ann Capaldi, Victor Manuel Villalobos, Monica Sheila Chatwal, Oliver Sartor
Institutions: Moores Cancer Center, Linkou Chang Gung Memorial Hospital, Hospital Universitario Ramón y Cajal, Royal Marsden Hospital, Duke University, Duke Cancer Institute, Essen University Hospital, Queensland Health, Princess Alexandra Hospital, Centre Hospitalier de l’Université de Montréal, Centre Léon Bérard, Sichuan University, West China Hospital of Sichuan University, Johnson & Johnson (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162686971
Cites:
Cited by:
Related to: